Velcade also triggers anticancer immune response in cell experiments
 

Velcade (bortezomib) which had previously been shown in lab experiments to enhance Herceptin's action on cancer cells (http://mct.aacrjournals.org/cgi/content/full/5/12/3042) is ,in this new article, shown to ellicite an immune reaction similar to an anticancer vaccine:
http://newswire.rockefeller.edu/?page=engine&id=594
A chemotherapy drug packs a one-two punch